Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,301

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,301 results for “retrospective study”

Learn how ShareScore rates datasets ↗
zenodo16/100

Dataset for "Muscle mass and Vitamin B6 are linked to negative body image in women with anorexia nervosa: a retrospective study."

<p>This is the dataset associated with the article "Muscle mass and Vitamin B6 are linked to negative body image in women with anorexia nervosa: a retrospective study."</p> <p>These data cannot be made publicly available because they include sensitive information, but they can be made available upon reasonable request of interested researchers to the Corresponding Author, who will forward a transfer agreement request to the relevant Ethical Committee.</p> <p>Requests should be addressed to Federica Scarpina (<a href="mailto:f.scarpina@auxologico.it">f.scarpina@auxologico.it</a>).</p>

restrictedcc-by-4.0Oct 2024View details →
zenodo16/100

A comparative assessment of the BioBiteCorrector® and Herbst appliances in the treatment of Class II malocclusion: a retrospective cohort study on treatment outcome

<p>Dataset for all analyses. Initially, access will be given to editor/reviewers for the peer review process. After publication, the dataset will be available openly for everyone.</p>

restrictedcc-by-4.0Oct 2024View details →
zenodo16/100

Dataset related to article "FOCAL CORTICAL DYSPLASIA IIIA IN HIPPOCAMPAL SCLEROSIS-ASSOCIATED EPILEPSY: ANATOMO-ELECTRO-CLINICAL PROFILE AND SURGICAL RESULTS FROM A MULTICENTRIC RETROSPECTIVE STUDY"

<p>XLSX clinical database: General characteristics, neuroimaging, and electroclinical features of BESTA patients included in the study</p>

restrictedAug 2021View details →
zenodo16/100

Dataset related to article "Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study "

<p>This record contains raw data related to article &ldquo;Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study&quot;</p> <p>Abstract</p> <p><strong>Introduction: </strong> There are no strong data regarding the treatment with biologics (especially for the most recent anti-IL-17 and anti-IL-23 drugs) of patients with psoriasis and concomitant viral hepatitis. We assessed the safety of biologic drugs in patients with psoriasis who are seropositive for hepatitis B or C and did not receive antiviral prophylaxis.</p> <p><strong>Methods: </strong> We conducted a retrospective single-center study. The efficacy of biologic treatments was evaluated by assessing the Psoriasis Area and Severity Index (PASI) score during all visits, for a minimum follow-up of 52 weeks. All patients were evaluated by a hepatologist before starting the treatment. They were monitored for reactivation of viral hepatitis.</p> <p><strong>Results: </strong> Twenty patients had positive markers of hepatitis B virus (HBV) or hepatitis C virus (HCV). Seventeen patients had positive markers of HBV infection, and four patients had antibodies for HCV (one patient had serologic evidence of both infections). Anti-IL-23 biologics were the most used in our population, with risankizumab being the most prescribed drug. No patient had evidence of viral reactivation during our study. Study limitations include its retrospective nature and our inclusion of patients with different serological status receiving different biologic drugs.</p> <p><strong>Conclusion: </strong> Biologic therapies (including anti-IL-23 drugs) appear to be safe in patients seropositive for HCV or HBV core antibody who did not receive antiviral prophylaxis.</p>

restrictedNov 2022View details →
zenodo16/100

Dataset related to article "Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study"

<p>This record contains raw data related to article &ldquo;Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study&quot;</p> <p>Abstract</p> <p><strong>Introduction: </strong> Risankizumab is a humanized monoclonal antibody that selectively targets interleukin-23. It is approved for treatment of moderate-to-severe plaque psoriasis. We conducted a 52-week monocentric retrospective study to evaluate the effectiveness and safety of risankizumab in a real-life setting.</p> <p><strong>Methods: </strong> Our study included 131 adults with moderate-to-severe plaque psoriasis all treated with risankizumab for at least 52 weeks. Patient characteristics and PASI (Psoriasis Area and Severity Index) at each visit were recorded. The percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI with respect to baseline were registered.</p> <p><strong>Results: </strong> At week 52, 93.9%, 78.6%, and 61.1% of patients achieved PASI 75/90/100, respectively. An absolute PASI &le; 2 was reached by 90.8% at week 52. The higher body mass index and the presence of cardio-metabolic comorbidities did not interfere with the odds of reaching PASI 75/90/100 at each time-point. At week 52, comparable percentages of patients achieved PASI 100, regardless of the involvement of difficult-to-treat-areas. No significant safety findings were recorded and none of the patients had to interrupt the treatment because of adverse events.</p> <p><strong>Conclusions: </strong> Our findings confirmed that risankizumab is a safe and effective therapeutic option for the treatment of a wide &quot;real-life&quot; cohort of patients with psoriasis.</p>

restrictedNov 2022View details →
zenodo16/100

Dataset related to article "Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study "

<p>This record contains raw data related to article &ldquo;Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study&quot;</p> <p>Abstract</p> <p>Scalp is a frequent localization of psoriasis that has a massive impact on patient&#39;s quality of life. Managing this psoriasis&#39; manifestation is often challenging, thus biologic drugs are widely used as a treatment option in refractory scalp psoriasis. The aim of our study is to retrospectively compare the efficacy of anti-interleukin (IL) 23 drugs (guselkumab, tildrakizumab, risankizumab) and anti-IL17 or anti-IL17RA biologics (secukinumab, ixekizumab, and brodalumab) in real-life patients affected by scalp psoriasis. One hundred twenty-seven patients with a clinical diagnosis of scalp psoriasis and a baseline scalp Physician Global Assessment &ge;3 were enrolled; 65 patients were treated with anti-IL23 and anti-IL62 with anti-IL17 or anti-IL17RA. Statistical analysis trough &chi;<sup>2</sup> test was performed in order to evaluate the percentage of response among the two groups of patients. Responders&#39; percentage of patients under anti-IL23 was 41.5%, 75.4%, 88.1%, 87.5%, 93.7%, and 100% at Week 4, 16, 48, 96, and 144, respectively. In the group on anti-IL17 was 62.9%, 90.3%, 91.2%, 97.3%, 96.9%, and 95.2% at Week 4, 16, 48, 96, and 144, respectively. Both anti-IL17 and anti-IL23 appeared to be effective on scalp psoriasis; in particular patients treated with anti-IL17 drugs reached a faster significant reduction of the lesions; on the other hand, anti-IL23 monoclonal antibodies were slightly superior in maintaining the clinical improvement through the follow-up.</p>

restrictedNov 2022View details →
zenodo16/100

Dataset related to article "Surgical treatment for vestibular schwannoma in patients aged ≥65-years: A retrospective multi-centric study "

<p>This record contains raw data related to article &ldquo;Surgical treatment for vestibular schwannoma in patients aged &ge;65-years: A retrospective multi-centric study&quot;</p> <p>The worldwide older population is significantly increasing in recent decades, particularly in Western countries. However, there is a lack of data regarding risks and benefits in neurosurgical practice for this subgroup of patients, which often leads to challenging decision-making processes.</p> <p>Vestibular schwannomas (VS) are <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/benign-tumor">benign tumors</a>, having a peak incidence in the 6th and 7th decades of life. VSs represent approximately 6&nbsp;% of all intracranial and 80&nbsp;% of cerebellopontine angle (CPA) tumors, and incidence rates are increasing over time, ranging from 0.2 to 1.7 per 100,000 population. Regarding the older population, the question of what should be the optimal treatment of VS is still a matter of debate. Indeed, life expectancy and physiological reserves for recovery are relatively lower in this subgroup of patients. Moreover, the presence of any underlying comorbidity could increase the risk of both intra and <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/postoperative-complication">postoperative complications</a> . In this context, most of the recent body of literature appears to favor conservative approaches (wait-and-see strategy) and other treatment options such as hypo-fractionated radiotherapy (RT) or <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/stereotactic-radiosurgery">stereotactic radiosurgery</a> (SRS). Nevertheless, in selected cases, surgical treatment could represent the method of choice some recent reports suggest that surgery could be a safe and feasible approach in selected cases. For instance, factors such as the presence of a large lesion leading to <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/hydrocephalus">hydrocephalus</a>, progressive neurological deficits due to compression of the surrounding neurovascular structures, cerebellar and/or <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/brainstem">brainstem</a> edema, and severe persistent <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/vestibular-disorder">vestibular dysfunction</a> must be considered and represent major criteria for surgery.</p> <p>In the present study, we reported our experience with 31 patients aged &ge;65-year-old who underwent surgical resection for VS.</p>

restrictedJan 2023View details →
zenodo16/100

: Dataset related to the article "Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study"

<p>This record contains raw data related to the article &ldquo;Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study&rdquo;.</p> <p><em><strong>Abstract</strong></em></p> <p><strong>Background:&nbsp;</strong>Advanced glycation end-products (AGEs) and their interaction with the receptor for advanced glycation end-products (RAGE) play a pivotal role in the development and progression of type 2 diabetes. In this retrospective cohort study, we explored the association of circulating levels of soluble RAGE (sRAGE) isoforms, i.e., endogenous secretory esRAGE and cleaved cRAGE, AGEs and their respective ratios with 15-year all-cause mortality in type 2 diabetes.&nbsp;<strong>Methods:&nbsp;</strong>Baseline AGEs and sRAGE isoforms concentration were measured by ELISA in 362 patients with type 2 diabetes and in 125 age- and gender-matched healthy control subjects (CTR). Independent predictors of mortality were determined using Cox proportional-hazards models and used to build and validate a nomogram for all-cause mortality prediction in type 2 diabetes.&nbsp;<strong>Results:&nbsp;</strong>AGEs, total sRAGE, cRAGE and the AGEs/sRAGE and AGEs/esRAGE ratios were significantly increased in patients with type 2 diabetes compared to CTR (p &lt; 0.001). In CTR subjects, but not in type 2 diabetes patients, a significant negative correlation between cRAGE and age was confirmed (p = 0.003), whereas the AGEs/sRAGE (p = 0.032) and AGEs/cRAGE (p = 0.006) ratios were positively associated with age. At an average follow-up of 15 years (4,982 person-years), 130 deaths were observed. The increase in the AGEs/cRAGE ratio was accompanied by a higher risk of all-cause mortality in patients with type 2 diabetes (HR per each SD increment = 1.30, 95% CI 1.15-1.47; p &lt; 0.001). Moreover, sRAGE was associated with the development of major adverse cardiovascular events (MACE) in type 2 diabetes patients without previous MACE (OR for each SD increase: 1.48, 95% CI 1.11-1.89). A nomogram based on age, sex, HbA1c, systolic blood pressure, and the AGEs/cRAGE ratio was built to predict 5-, 10- and 15-year survival in type 2 diabetes. Patients were categorized into quartiles of the monogram scores and Kaplan-Meier survival curves confirmed the prognostic accuracy of the model (log-rank p = 6.5 &times; 10<sup>- 13</sup>).&nbsp;<strong>Conclusions:&nbsp;</strong>The ratio between AGEs and the cRAGE isoform is predictive of 15-year survival in patients with type 2 diabetes. Our data support the assessment of circulating AGEs and soluble RAGE isoforms in patients with type 2 diabetes as predictors of MACE and all-cause mortality.</p> Enable Ginger<em>Cannot connect to Ginger</em> Check your internet connection<br> or reload the browserDisable in this text fieldRephraseRephrase current sentence<span class="ginger-floatingG-bar-tool-mistakes-count">26</span>Log in to edit with Ginger&times;

restrictedJan 2023View details →
zenodo16/100

Datset related to article "Pathways of follow-up care in an Italian center: retrospective study on patients with gliomas II and III"

<p>Database related to the descriptive statistics used to illustrate the characteristics of the sample and to identify the pathways of follow-up care in an Italian center.</p>

restrictedFeb 2023View details →
zenodo16/100

Validation of a clinicopathological classification for predicting outcomes of pituitary tumours: retrospective cohort study in a pituitary tumour centre of excellence, 2013–2023

<p><strong>Simple Summary:</strong> This retrospective study aims to classify a series of pituitary neuroendocrine tumours (PitNETs), typified according to the WHO 2017 recommendations, using Trouillas et al.&rsquo;s clinicopathological classification from 2013. We analysed 166 patients who underwent PitNET surgery from 2013 to 2023. The tumours were identified according to the gene and immunohistochemistry expression of pituitary transcription factors and adenohypophyseal hormones. The PitNETs were graded based on the invasion observed in MRI and the Ki-67 index. The study found that grade 2a and 2b tumours, T2 signal intensity ratio (SIR), and silent corticotroph tumours were associated with lower progression-free survival rates. Tumour volume and T2 SIR were independent predictors of recurrence/progression, with a T2 SIR of 2 or more showing a significantly higher risk. These findings emphasise the prognostic value of the five-grade classification and underscore the importance of radiological evaluation for managing PitNETs.</p> <p>&nbsp;</p> <p><strong>Abstract: </strong>Immunostaining of transcription factors allows a more exact classification of pituitary neuroendocrine tumours (PitNETs), but not a better prediction of their clinical behaviour. This retrospective, single-centre study aims to classify a series of PitNETs using Trouillas et al.&rsquo;s clinicopathological classification from 2013. We analysed 166 patients undergoing PitNET surgery in 2013&ndash;2023. Tumours were identified according to the gene and immunohistochemical expression of PitNET transcription factors plus adenohypophyseal hormones. Tumours were classified according to a grading system based on MRI invasion and Ki-67 index. Eighty-one (48.8%) patients had grade 2a tumours; 71 (42.8%), grade 1a; 8 (4.8%), 2b; and 6 (3.6%), 1b. At a mean follow-up of 57.8 (standard deviation 30) months, 13.9% (n=23) showed recurrence/progression; independent predictors of recurrence were tumour volume (p=0.031) and T2 signal intensity ratio (SIR) (p&lt;0.001). This risk was 18.6-fold higher for a T2 SIR of 2 or more. Grade 2a and 2b tumours, T2 SIR, and silent corticotroph adenomas (SCAs) were associated with lower progression-free survival. Our results add more evidence to the prognostic value of the five-grade PitNET classification and suggest higher clinical surveillance of patients with SCAs is warranted. The MRI findings highlight the increasing value of radiological evaluation for managing PitNETs.</p>

restrictedJul 2023View details →
ClinicalTrials.gov16/100

Clinical Outcome of Neonates With GBS Positive Culture-12 Year Retrospective Study

ClinicalTrials.gov study NCT00326313. IPD Sharing: Not stated. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
geo12/100

Retrospective study of 186 fetuses with sex chromosomal copy number variations

GEO Series GSE208389. Homo sapiens. 185 samples. Type: SNP genotyping by SNP array; Genome variation profiling by SNP array.

openGEO-OpenJul 2022View details →
geo12/100

ENCODE cell phenotype retrospective study

GEO Series GSE12760. Homo sapiens. 41 samples. Type: Expression profiling by array.

openGEO-OpenSep 2008View details →
zenodo12/100

Peribulbar vs. incisionless sub-Tenon's blocks: analysis of complication profiles: a retrospective cohort study

Open the record for dataset details and reuse information.

restrictedcc-by-4.0Nov 2024View details →
zenodo12/100

Dataset related to article "Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study"

<p>This record contains raw data related to article &ldquo;Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study&quot;</p> <p>Palmoplantar psoriasis (PP) is a type of psoriasis that involves the skin of the palms and soles and can present as hyperkeratotic, similar to the vulgaris psoriasis of the body. Apremilast, as an oral inhibitor of phosphodiesterase 4 (PDE4), is currently approved for the treatment of psoriatic arthritis and for moderate-to-severe psoriasis in adult patients who have not responded or have contraindications or do not tolerate other systemic treatments. We evaluated the efficacy and safety of apremilast in the treatment of non-pustular palmo-plantar psoriasis in a cohort of 12 patients. We found a clinical response of clear/almost clear palmoplantar psoriasis (PPPGA score 0/1) in 83.33% of our patients, at week 16. No significant safety issues were reported and none of our patients had to discontinue the drug.</p> <p>&nbsp;</p> <p>&nbsp;</p>

restrictedFeb 2022View details →
zenodo12/100

Adolescents and Young Adults (AYA) melanoma: Evaluation of the characteristics, treatment strategies, prognostic factors in a monocentric retrospective study

<p>Melanoma is rare in children, it has greater incidence in adolescents and young adults (AYA). Few studies have specifically addressed the topic of AYA melanoma.&nbsp; The aim of this study is to describe characteristics, treatment, and prognosis of a series of cases of melanoma in adolescents and young adults in order to contribute to the investigation of this malignancy and provide better patient care. This is a retrospective cohort-based study including patients over 15 years of age at diagnosis from Veneto Region, who received diagnosis and/or treatment from our institutions between 1998 and 2014. We divided the patients in three subgroups: adolescents (15-25 years), young adults (26-39 years) and adults (more than 39 years). &nbsp;Among the three groups there was statistically significant difference in gender, primary site, Breslow thickness, ulceration, pTNM stage and tumoral subtype, disease-specific overall survival and disease-free survival.</p>

restrictedMay 2021View details →
zenodo12/100

Assessment of Sticky Bone in one- stage Lateral Sinus Lift Procedures: A 4 year retrospective study

Open the record for dataset details and reuse information.

restrictedcc-by-4.0Jun 2024View details →
zenodo12/100

Fluorine-18 fluorodeoxyglucose (FDG)-uptake assessment of PDGFRɑ mutant gastrointestinal stromal tumors (GIST): an Italian retrospective multicenter study

Open the record for dataset details and reuse information.

restrictedcc-by-4.0Jul 2024View details →
zenodo12/100

A retrospective study of Crimean-Congo hemorrhagic fever in Iraq

<p>Background: CCHF is transmitted via ticks biting and directly by contact with tissue or blood of infected patients or viremic<br>animals. This study intends to determine the occurrence of CCHF in Iraq between 2015 and 2019.<br>Methods: This study was designed as a retrospective and descriptive cross-sectional study. It was approved the occurrence of<br>CCHF in Iraq with relation to some epidemiological and demographic data reported in the Iraqi Communicable Diseases Control<br>Center (CDC)/zoonotic diseases section between 2015-2019.<br>Results: Out of 206 suspected cases, only 17 were diagnosed as CCHF with a total fatality ratio of 52%, 25%, and 80% in 2015<br>and 2018 respectively. However, no mortality was reported during 2016, 2017, and 2019. The mean age of the patients was 33<br>years&plusmn; 18 SD, in males mainly (76%). Moreover, the risk groups were 29 %, 23 %, 18 % 12 %, and 6 % for butchers, animal<br>dealers, gainers, both housewives and students and children respectively.<br>Conclusion: Strict precautions and precise surveillance should be implemented to control the disease and protect the community<br>by improving the diagnosis and treatment of CCHF. The authors recommend another future study to detect the genotyping<br>and sequencing of CCHFV in Iraq.</p>

embargoedMar 2024View details →
zenodo12/100

Retrospective Multicenter Study on the Diagnostic Accuracy of 18-F FDG PET/CT for suspected Prosthetic Valve Endocarditis

<p>Collaborative database of 6 academic centres in the Netherlands containing anonymized data of 18F-FDG PET/CT scans of patients with a prosthetic heart valve.&nbsp;</p>

restrictedMar 2018View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.